About
Technology
Issues
FAQ
Links
Official Page
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.